Sarah Elizabeth Yentz, MD, discusses treatment considerations in patients with favorable-risk renal cell carcinoma.
Sarah Elizabeth Yentz, MD
Advertisement
Articles by Sarah Elizabeth Yentz, MD
Sarah Elizabeth Yentz, MD, discusses how she decides between an immunotherapy agent plus a TKI combination vs 2-agent immunotherapy for patients with renal cell carcinoma.
Sarah Elizabeth Yentz, MD, discusses translating data to real-world clinical practice in renal cell carcinoma.
Sarah Elizabeth Yentz, MD, discusses unmet needs in metastatic renal cell carcinoma.
Sarah Elizabeth Yentz, MD, discusses navigating frontline treatment selection in renal cell carcinoma.
Advertisement
Latest Updated Articles
Dr Yentz on Treatment Decisions for Patients With Kidney CancerAugust 17th 2023
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles
4
Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS
5